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Abstract
Background: PI3K/AKTsignaling pathway plays an important role in cell growth, proliferation, and
tumorgenesis of various malignancies. This signaling pathway has been shown to be frequently
altered in several human cancers including ovarian cancers. However the role of this oncogenic
signaling pathway has not been explored in the Middle Eastern epithelial ovarian cancer (EOC).
Therefore, we investigated PI3K/AKT genetic alterations such as PIK3CA amplification, PIK3CA
mutation, PTEN protein loss and their relationships with various clinicopathological characteristics
in 156 EOCs.
Results: Fluorescence in situ hybridization (FISH) technique and DNA sequencing were used to
analyze PIK3CA amplification and mutation respectively. Expression of PIK3CA protein expression
(p110 α), PTEN, p-AKT and Ki-67 was analyzed by immunohistochemistry. PIK3CA amplification
was seen in 54 of 152 (35.5%) EOC cases analyzed; PIK3CA gene mutations in 6/153 EOC (3.9%);
KRAS mutations in 3/154 EOC (1.9%), BRAF mutations in 3/156 EOC (1.9%), p53 mutation in 50/
154 EOC (32.5%), and loss of PTEN protein expression in 33/144 EOC (22.9%). p110 α
overexpression was associated with increased phosphorylation of AKT-Ser 473 and with the
proliferation marker Ki-67.
Conclusion:  Our data showed mutual exclusivity between the molecular event of PIK3CA
amplification and mutations in PIK3CA,  KRAS,  BRAF  genes, which suggests that each of these
alterations may individually be sufficient to drive ovarian tumor pathogenesis independently. High
prevalence of genetic alterations in PI3K/AKT pathway in a Middle Eastern ovarian carcinoma
provides genetic evidence supporting the notion that dysregulated PI3K/AKT pathways play an
important role in the pathogenesis of ovarian cancers.
Background
Ovarian carcinoma is the most lethal gynecological malig-
nancy because most tumours are detected in advanced
stages [1,2]. It is the fifth leading cause of cancer-related
death among U.S. women. In Middle Eastern ovarian can-
cer, a similar pattern of incidence has been seen [3]. Epi-
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thelial cancer of the ovary derives from malignant
transformation of the epithelium of the ovarian surface,
which is contiguous with the peritoneal mesothelium
[4,5]. Epithelial ovarian neoplasms are subclassified his-
tologically into serous, mucinous, endometrioid, clear
cell, transitional (Brenner), squamous cell, and undiffer-
entiated subtypes. Serous carcinomas (SC) are the most
common histology, accounting for about two thirds of
ovarian carcinomas [6]. A better understanding of the fac-
tors and mechanisms determining the aggressive behavior
of some EOC is critical in developing new treatment.
Increased mitogenic signaling through receptors has
proven to play a major role in ovarian cancer. One of the
major downstream mediators of signaling initiated by
these receptors is the phosphatidylinositol 3-kinase
(PI3K)/AKT pathway. PI3K/AKT is activated in multiple
cancers leading to oncogenic transformation [7,8]. Activa-
tion may result from activating mutation of the catalytic
subunit of p110α of PIK gene (PIK3CA) or amplification
of PIK3CA or as a result of inactivating mutation in the
tumor suppressor gene, phosphatase and tensin homolog
(PTEN). Activation of this pathway will cause AKT to
translocate to the plasma membrane, where it is activated
by phosphorylation allowing it to mediate many of the
biological consequences of PI3K activation. Several stud-
ies have showed PIK3CA gene amplification in ovarian
cancers [9-13]. Mutations in the PIK3CA have also been
identified in ovarian cancers and though relatively com-
mon in endometrioid ovarian carcinomas (EC), are
uncommon in serous carcinomas (SC) [11].
Rat sarcoma viral oncogene (RAS) proteins are located on
the inner surface of the plasma membrane and are
attached to the membrane by a farnesyl residue. RAS pro-
teins transmit extracellular signals that promote the
growth, proliferation, differentiation and survival of cells.
The major downstream target of RAS-GTP is mitogen-acti-
vated protein kinases (MAPKs), but it is also known to
activate other targets like PI3K [14,15]. The MAPK path-
way is hyperactivated in 30% of human cancer [14]. RAS
mutation can promote ovarian tumorigenesis through
MAPK pathway or through its interaction with PI3K/AKT
pathway [14,15]. In ovarian cancer, KRAS mutation has
been identified in 35% low-grade serous tumors and 33%
of borderline tumors, whereas, BRAF mutations occur in
30% of low-grade serous carcinomas and 28% of border-
line tumors [16,17]. KRAS and BRAF mutations are less
common in high grade ovarian cancers [16,17].
Several pervious studies have shown the oncogenic role of
PI3K/AKT pathway in EOC. Elucidation of the characteris-
tics of ovarian cancer with PI3K alterations seems to be
important for the execution of personalized medicine in
future. However, all the studies on PI3K alteration
reported until now dealt with Caucasian ovarian cancers.
It seems interesting to compare the frequency of PI3K
alterations between two ethnicities, Middle Eastern and
Caucasian EOC, and explore the contribution of PI3K
alterations to pathogenesis of Middle Eastern EOC. There-
fore, in the present study, we have analyzed the prevalence
of genetic alterations of PI3K in Middle Eastern EOC and
their interrelationships with other genetic alterations like
p53, KRAS and BRAF. Furthermore, correlation of the
PI3K alterations with various clinicopathological charac-
teristics was investigated in a large cohort of Middle East-
ern EOCs.
Methods
Patient selection and tissue microarray construction
156 patients with ovarian carcinoma diagnosed between
1991–2007 were selected from the files of the King Faisal
Specialist Hospital and Research Centre. All samples were
analyzed in a tissue microarray (TMA) format. TMA con-
struction was performed as described earlier [18,19]. Two
cores of ovarian carcinoma were arrayed from each case.
The Institutional Review Board of the King Faisal Special-
ist Hospital & Research Centre approved the study.
The patients were diagnosed histologically and received
follow-up care in the Departments of Obstetrics and
Gynecology and Oncology at King Faisal Specialist Hospi-
tal and Research Centre. The histological subtype of each
ovarian tumor sample was determined by pathologist
(PB) according to accepted criteria [20]. Department of
Obstetrics and Gynecology, King Faisal Specialist Hospital
and Research Center provided long-term follow-up data
for these patients. The primary pathological diagnosis was
serous 125 patients (80.1%), endometrioid in 22
(14.1%), clear cell in 4 (2.6%) and undifferentiated/
mixed Epithelial in 5 (3.2%). The ages of the patients
ranged from 19–86 years, with a median age of 56 years.
The majority of patients underwent primary surgical stag-
ing or cytoreduction. In some patients who were not fit for
primary surgery, primary neoadjuvant chemotherapy was
followed by interval debulking surgery. The distribution
by FIGO stage at diagnosis was: stage I-II in 8 patients
(5.1%), stage III-IV in 137 (87.8%), and unknown in
11(6.1%). The median follow-up time was 14.9 months
(range, 2–130 months). Progression free survival was
computed from date of surgery for patients who under-
went primary cytoreduction and from date of diagnosis by
biopsy or cytology in those who underwent primary neo-
adjuvant chemotherapy. Since the majority of patients are
lost to follow-up as their disease reaches its terminal
stages, it was impossible to determine overall survival in
this specific patient population.Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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DNA extraction and purification
Genomic DNAs were extracted from paraffin embedded
neoplastic primary tissues using Gentra Kit (Minneapolis,
MN, USA) following a slight modification to the manu-
facturer's recommendation.
Mutation analysis of PIK3CA, p53, KRAS, and BRAF genes
Step-down cycling condition was used for BRAF T1799A
transversion mutation in exon 15 of the BRAF gene [21].
After a 10-min denaturing at 95°C, the PCR was run with
each temperature for 1 min at five step-down steps, for
two cycles each. The denaturing temperature was 95°C,
and extension temperature was 72°C for each step, with
the annealing temperature of 66, 64, 62, 60 and 58°C
from the first to the last step. The PCR was finally run at
95, 58, and 72°C each for 1 min for 35 cycles, followed by
an elongation at 72°C for 5 min. PCR was performed in a
total volume of 25 μL using 50 ng of genomic DNA, 2.5
μL 10 × Taq buffer, 1.5 μL MgCl2 (25 mM), 0.05 μL dNTP
(10 mM), 0.2 μL Taq polymerase (1 U/μL) (all reagents
were from Qiagen Inc), 1 μL of each primer (2.5 μM), and
water. As majority of KRAS mutations were found in exon
1 of KRAS gene, we focused our mutation analysis on
KRAS.[21] The PCR mixture contained the same compo-
nents as in PCR reaction for the BRAF gene. The PCR con-
dition was as follows: after a 10 min denaturation at
95°C, 30 s of annealing at 53°C, and 1 min of extension
at 72°C, with an extension of 72°C for 7 min at the last
step [21]. The efficiency and quality of the amplification
PCR were confirmed by running the PCR products on a
2% agarose gel. The PCR products were subsequently sub-
jected to direct sequencing PCR with BigDye terminator V
3.0 cycle sequencing reagents (Applied Biosystems, Foster
City, CA). The samples were finally analyzed on an ABI
PRISM 3100 xl Genetic Analyzer (Applied Biosystems,
Foster City, CA). Sequencing of PIK3CA exons 9, 20 was
done by PCR amplification and direct sequencing of both
strands for all CRC cases and their matched normal sam-
ples as previously described [22,23].
For p53 mutational analysis, exons 5–8 of the P53 gene
were amplified separately as previously [24]. The follow-
ing primers were used: exon-5-forward: 5'GACTT-
TCAACTC-TGTCTC3', reverse:
5'CTGGGGACCCCTGGGCAAC3'; exon-6-forward:
5'GAGAC-GACAGGGCTGGTT3', reverse: 5'CCACTGAC-
AACCACCCTT3'; exon-7-forward
5'CCAAGGCGCACTGGCCTC3', reverse:
5'GCGGCAAGCAGAGGCTGG3'; and exon-8-forward:
'CCTTACTG-CCTCTTGCTT3', reverse 5'TGAATCTGAG-
GCATAA-CTGC3'. The samples were finally analyzed on
an ABI PRISM 3100 xl Genetic Analyzer (Applied Biosys-
tems, Foster City, CA). Mutational analysis was done
using DNA SEQMAN software (DNASTAR Inc., Madison,
WI).
Immunohistochemistry (IHC)
TMA slides were processed and stained manually. The
streptavidin-biotin peroxidase technique with diami-
nobenzidine as chromogen was applied. For antigen
retrieval, Dako Target Retrieval Solution pH 9.0 (Cata-
logue number S2368) was used, and the slides were
boiled in a pressure cooker (Pascal Pressure Cooker, Dako
Cytomation, Model: S2800, USA). Primary antibodies
used, their dilutions, and incidences are listed in Table 1.
Endogenous peroxidase activity was quenched using 3%
hydrogen peroxidase. Endogenous biotin was blocked
and all slides were counterstained with hematoxylin,
dehydrated, cleared, and cover slipped with premount.
Only fresh cut slides were stained simultaneously to min-
imize the influence of slide ageing and maximize repeata-
bility and reproducibility of the experiment.
p-AKT scoring was done as described earlier [21,25]. For
purposes of statistical analysis, all cases staining at level 0
Table 1: Antibodies used for tissue microarray Immunohistochemical analysis
Antibody 
(Subcellular 
Localization)
$Positive 
cases (%)
Clone Company Source Dilution 
Overnight in 
incubation
Retrieval Detection System
PTEN@ 111/144
77.1%
6H2-1 Cascade 
Bioscience
Mouse 
monoclonal
1:100 pH 9, Pressure 
Cooker
EnVision+
p-AKT
(Cytoplasmic & 
Nuclear)
75/144
52.1
Ser473 Cell Signaling Mouse
Mono-clonal
Predilute pH 9, 
microwave
Survival Marker; Signal 
Stain IHC detection 
Kit
PIK3CA-110 78/140
55.7%
1G12E9 Everest 
Biotech
Goat 
Polyclonal
1:400 pH 6, Pressure 
Cooker
EnVision+
P53 68/138
49.3%
DO-7 D9K0 Mouse 
monoclonal
1:50 pH 9, 
microwave
Ventana Bechmark
@Normal expression of PTEN was seen in 77.1% cases and PTEN inactivation (loss/reduced expression) was seen in 33/144(22.9%) of EOC cases.
$ Non representative spots for the various antibodies ranged from18 cases for p53 to 12 spots for PTEN IHCMolecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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or 1 were grouped as p-AKT negative and all cases staining
at level 2 and level 3 were grouped as p-AKT positive. For
PTEN scoring cases staining at level 2 or 3 were considered
as normal expression and cases staining at level 0 or 1
were considered to have PTEN inactivation. Only fresh cut
slides were stained simultaneously to minimize the influ-
ence of slide ageing and maximize repeatability and
reproducibility of the experiment. Two types of negative
controls were used for p-AKT. One was the negative con-
trol in the kit in which the primary antibody was omitted.
A preabsorption experiment using p-AKT Ser 473 blocking
peptide (Cell Signaling Technology, Beverly, MA, Product
No 1140) was used as the second negative control.
PIK3CA protein (p110 α expression) was categorized by
doing an H score as described earlier [26]. Each TMA spot
was assigned an intensity score from 0–3(I0, I1–3) and pro-
portion of the tumor staining for that intensity was
recorded as 5% increments from a range of 0–100(P0, P1–
3). A final H score (range 0–300) was obtained by adding
the sum of scores obtained for each intensity and propor-
tion of area stained (H score = I1XP1+I2XP2+I3XP3). Ovar-
ian tumors were grouped into 2 groups using X-tile
bioinformatics software: low p110 α expression (H score
= 100) and the other group showed high p110 α expres-
sion (H score >100) [27].
Flourescent in situ hybridization (FISH) methodology
FISH on tissue micorarray was performed as previously
described [21]. Briefly the search for FISH probe was done
by browsing Ensemble Genome Browser http://
www.ensembl.org/ for bacterial artificial chromosome
(BAC) corresponding to PIK3CA  gene. BAC RP11-245
C23 was purchased from Childrens Hospital Oakland
Reseach Institute (Oakland, California), was cultured and
DNA isolated. BAC DNA probe was labeled with digoxi-
genin using the DIG-nick translating kit from Roche. FISH
was performed with a digoxigenin-labeled BAC DNA
probe, containing the PIK3CA  gene and a Spectrum
Orange-labeled chromosome 3 centromeric probe
(CEP3) as a reference (purchased from Vysis). TMA sec-
tions were treated according to the Paraffin Pretreatment
Reagent Kit protocol (Vysis, IL, USA) before hybridiza-
tion. For the ovarian cancer TMA study, hybridization and
post-hybridization washes were according to the Vysis LSI
procedure. Probe visualization using fluorescent isothio-
cyanate (FITC)-conjugated sheep anti-digoxigenin (Roche
Diagnostics, Indianapolis, IN, USA) was as described
(Wagner et al). Slides were then counterstained with 125
ng/ml 4',6-diamino-2-phenylindole in an antifade solu-
tion and screened with a Olympus BX51 fluorescent
microscope. Tissue samples were classified with a
PIK3CA/centromere 3 ratio of 1.0 as normal, between 1.0
and 2.0 as having PIK3CA gains. A PIK3CA/centromere 3
ratio of more than 2.0 was considered as amplified.
Quantitative real-time PCR
Ovarian tumors with increased copy number by FISH of
PIK3CA gene were selected for validation by quantitative
real time PCR. DNA content was normalized to that of
long interspersed elements (LINE1), a repetitive element
for which copy number per haploid genome are similar
both in normal DNA sample and neoplastic cells. Primers
were designed by Primer express 3.0 software (Applied
Biosystems Foster City CA) hybridize to sequences of
genomic DNA for PIK3CA  and  LINE 1. Primers to
genomic sequences were (PIK3CA forward, 5'-TATGGTT-
GTC-TGTCAATCGGTGA-3'; reverse,5'-GCCTTTGCAGT-
GAATT-TGCAT-3') and (LINE1 forward, 5'-
CCGCTCAACTACATGGAAACTG-3' reverse, 5'-GCGTC-
CCAGAGATTCTGGTATG-3'). Conditions for all PCRs
were optimized in gradient cycler (MJ Research, MA,
United States) with regard to Taq DNA polymerase, for-
ward and reverse primers, MgCl2 concentrations, dNTP
concentrations and various annealing temperatures (55–
65°C). Specificity of the PCR product was confirmed by
agarose gel electrophoresis. Optimized results were trans-
ferred on the following Light Cycler PCR protocol.
All reactions were performed in glass capillaries (Roche,
Mannheim, Germany) with a final reaction volume of 10
μl of 1× LightCycler-FastStart DNA Master SYBR Green I
reaction mixture (Roche, Mannheim, Germany) contain-
ing FastStart Taq, reaction buffer, and deoxynucleoside tri-
phosphate, 1 mM MgCl2, and final concentrations of 0.5
μM for each primer. MgCl2 concentrations were optimized
for each target gene (varied from 2–4 mM). Thermocy-
cling and detection were performed on the LightCycler
(Roche Diagnostics, Mannheim, Germany). An initial pre-
heating step of 10 min at 95°C was used to activate the
DNA polymerase, then, a touch-down procedure, consist-
ing of 10 s at 95°C, annealing for 5 s at temperatures
decreasing from 63 to 59°C, and ending with an exten-
sion step at 72°C for 10 s. A total of 45 cycles were per-
formed, followed by melting curve program (60–95°C
with a heating rate of 0.1°C per second and a continuous
fluorescence measurement), and finally a cooling step to
40°C.
Pfaffle method for relative quantification was used to cal-
culate fold of changes for normal and ovarian cancer sam-
ples [28]. The relative copy number ratio of a target gene
is calculated based on efficiency (E) and crossing point
(CP) deviation of samples (normal) versus (ovarian
tumor), and expressed in comparison to a reference gene
(LINE1). For a normal cell the copy number of a gene per
haploid genome should be one.
Statistics
All Statistical analysis will be performed using the
Statview JMP software (version 7.0). Fisher's exact chi-Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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square (χ2) test was used to assess associations between
categorical variables. Kaplan-Meier survival analyses were
carried out for progression free survival, using the log-
rank test for differences between groups. Results were con-
sidered statistically significant when p from a two-tailed
test was < 0.05.
Results
PIK3CA mutations, PIK3CA amplification and PIK3CA 110 
alpha subunit protein expression (p110 α expression) in 
EOC
PIK3CA mutation was seen in 6 of 153 (3.9%, Fig. 1)
EOC's analyzed and FISH analysis revealed the presence
of PIK3CA amplification in 54 of 152 (35.5%, Fig. 2) EOC
cases analyzed. PIK3CA amplification results were further
validated by real-time PCR. No significant associations
were observed with PIK3CA mutations or PIK3CA ampli-
fications and clinicopathological parameters. Immuno-
histochemical analysis showed overexpression of p110 α
expression in 78 of 140 (55.7%, Fig. 3) EOC cases ana-
lyzed and its association with various clinicopathological
parameters was analyzed (Table 2). p110 α expression
overexpression did not coorelate with age, tumor stage,
FIGO grade and progreesion free survival. PIK3CA 110
overexpression was associated with overexpression of p-
AKT-Ser 473 (p = 0.0260) and a trend was noted with the
proliferation marker Ki-67 (p = 0.0639). Of the 6 EOCS
with PIK3CA mutation, 5 of them showed overexpression
of PIK3CA 110 protein. No association was seen with
PIK3CA amplification and overexpression of p110 α
expression (p = 0.2320).
Examples of PIK3CA, KRAS, and BRAF mutations in EOC cases Figure 1
Examples of PIK3CA, KRAS, and BRAF mutations in EOC cases. A. Typical sequencing traces of PIK3CA mutations 
are shown for exon 9 (right) and 20 (left) with cancer mutant sequence (bottom) and normal wild-type sequence (top). B. 
Sequencing traces of BRAF (right) and KRAS (left) mutations with cancer mutant sequence (bottom) and normal wild-type 
sequence (top). Arrows denote position of the missense mutations with amino acid changes noted.Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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KRAS, BRAF, and TP53 mutation analysis
We found that six EOCs contained PIK3CA mutation,
three EOC contained activating KRAS mutations and three
EOCs had BRAF mutations at codon 599 (Fig. 1). The
presence of KRAS  and  BRAF  mutations was mutually
exclusive. EOCs with PI3K mutation did not display BRAF
or KRAS mutations. Thus PIK3CA mutations were also
mutually exclusive with KRAS and BRAF mutation.
TP53 mutation analysis revealed a mutation incidence
rate of 32.5% (50 of 154). No significant associations
were found between TP53 mutations and clinicopatho-
logical data like FIGO staging, tumor grading, tumor type,
patient age and progression free survival. Also TP53 muta-
tions were not associated with mutations in PIK3CA,
BRAF, and KRAS genes or with activation of AKT, loss of
PTEN expression and PIK3CA amplification.
Using the mouse monoclonal anti p53 antibody (Table
1), p53 overexpression by immunohistochemistry was
seen in 68/138 (49.3%) EOCs analyzed. p53 overexpres-
sion was significantly associated with p53 mutations (P =
0.0002) and a trend of increased expression noted in
poorly differentiated EOCs (P = 0.0961).
AKT activation in EOC and its correlation with PIK3CA 
mutations, PIK3CA amplification, KRAS, BRAF mutations
Because it is suggested that PIK3CA mutations activate
AKT function through its phosphorylation [29], we inves-
tigated the relationship between PIK3CA mutation,
Determination of PIK3CA gene copy number by FISH on ovarian tissue (A) Figure 2
Determination of PIK3CA gene copy number by FISH on ovarian tissue (A). B. Sample 1 is normal cell selected 
according to FISH analysis. Samples 2–4 are PIK3CA amplified ovarian tumor cells selected according to FISH. FISH images 
show cell nuclei (blue) from selected cases, hybridized with probes directed against PIK3CA gene (green RP11-245 C23) and 
centromere 3 (red). (1). Normal cell (blue) shows 2 centromeric signals (red) and 2 (green) PIK3CA signals. (2–4). Represent-
ative cells show amplification two (red) centromeric signals and green PIK3CA amplified Signals.Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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PIk3CA amplification and activation of p-AKT. The corre-
lation between the activation of AKT with clinicopatho-
logical parameters and mutational status of K-KRAS and
BRAF genes and TP53 mutation was also explored. AKT
activation was evaluated by assessing phosphorylation of
AKT by immunohistochemistry at Ser473 and an EOC
case was considered to show AKT activation when it was
scored as 2+ or 3+ for p-AKT Ser 473. Activation of AKT
was observed in 52.1% (75 of 144) of EOC cases.
Though p-AKT Ser 473 overexpression correlated signifi-
cantly with proliferation marker, Ki-67 expression (p =
0.0262), no association was seen with clinicopathological
parameters including progression free survival. Also there
was a lack of association between EOCs that harbored
KRAS mutations or BRAF mutations and AKT activation.
PTEN inactivation
All the EOC cases with lost or reduced PTEN expression
were considered as EOCs with PTEN inactivation. PTEN
inactivation was seen in 33 of 144 (22.9%) EOC's ana-
lyzed and was associated with histology subtype of clear
cell and undifferentiated carcinomas (p = 0.0491); overex-
pression of p53 protein (p = .0413) and a trend was seen
with older age (p = 0.0936). No significant associations
were noted with clinicopathological features and the vari-
ous mutations analyzed.
Immunohistochemical analysis of p-AKT, PI3K-110 alpha subunit protein expression and PTEN in epithelial ovarian carcinoma  (EOC) Figure 3
Immunohistochemical analysis of p-AKT, PI3K-110 alpha subunit protein expression and PTEN in epithelial 
ovarian carcinoma (EOC). (i) p-AKT over expression was observed along with (iii) low PTEN expressionand (v) over 
expression of PI3K-110 alpha in EOC TMA specimen and, (ii) Low expression for p-AKT was seen along with (iv) high PTEN 
expression and (vi) reduced expression for PI3K-110 alpha in EOC TMA specimen. 20 × magnifications with the inset showing 
a 100 × magnified view of the same.Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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Table 2: Correlation between PIK3CA-110-Alpha status and clinicopathological features in Epithelial Ovarian Carcinoma
High p110 α expression Low p110 α expression P value
N% N % N %
Total Number of Cases 140 78 55.7 62 44.3
Age
< = 50 years 54 38.6 31 57.4 23 42.6 0.7491
> 50 years 86 61.4 47 54.7 39 45.3
Tumour Stage
Stage I-II 8 6.1 4 50.0 4 50.0 0.7525
Stage III-IV 122 93.9 68 55.7 54 44.3
Histopathology
Clear cell 4 2.9 3 75.0 1 25.0 0.8585
Endometriod 19 13.6 11 57.9 8 42.1
Serous 113 80.7 62 54.9 51 45.1
Undifferentiated 4 2.9 2 50.0 2 50.0
FIGO Grade
Well differentiated 27 19.3 12 44.4 15 55.6 0.4114
Moderately Diff 73 52.1 42 57.5 31 42.5
Poorly Diff 40 28.6 24 60.0 16 40.0
PAKT (Ser473)
High (2–3) 69 51.5 46 66.7 23 33.3 0.0260
Low (0–1) 65 48.5 31 47.7 34 52.3
PTEN
Low (0–1) 31 23.3 17 54.8 14 45.2 0.7675
High (2–3) 102 76.7 59 57.8 43 42.2
Ki-67
Above 50 51 37.0 34 66.7 17 33.3 0.0639
Below = 50 87 63.0 44 50.6 43 49.4
P53
Negative 65 50.0 37 56.9 28 43.1 0.5923
Positive 65 50.0 40 61.5 25 38.5
KRAS Mutation
Present 2 1.4 0 0.0 2 100.0 0.0720
Absent 136 98.6 76 55.9 60 44.1
BRAF Mutation
Present 3 2.1 1 33.3 2 66.7 0.4302
Absent 137 97.9 77 56.2 60 43.8
PIK3CA Mutation
Present 6 4.4 5 83.3 1 16.7 0.1298
Absent 131 95.6 70 53.4 61 46.6
P53 Mutation
Present 47 34.1 25 53.2 22 46.8 0.7497
Absent 91 65.9 51 56.0 40 44.0
PIK3CA FISH
Amplified 49 35.5 24 49.0 25 51.0 0.2320
Non-Amplified 89 64.5 53 59.6 36 40.4
PFS-Median (months) 16.2 17.1 0.6578Molecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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Mutual exclusivity among the genetic alterations in the 
PI3K/Akt and MAPK pathways in Middle Eastern EOC 
cases
Because PIK3CA copy gain is the most common genetic
alteration in the PI3K/Akt pathway in EOCs in this Middle
Eastern cohort, we analyzed its relationship with each of
the gene mutations in the PI3K/Akt pathway. As shown in
Table 3, PIK3CA gene copy gain was uncommonly over-
lapped with gene mutations in EOC; mutations were
mostly seen in the group of EOC without PIK3CA copy
gain. The mutual exclusivity between PIK3CA copy gain
and any of the PIK3CA, KRAS, and BRAF mutations was
not statistically significant, probably due to the small
number of each of these mutations. There was not a single
overlap among these alterations. Additionally, the major-
ity of the amplified PIK3CA cases harbored normal PTEN
protein expression. However, overlap between the PTEN
protein loss and PIK3A  amplification was seen in a
number of cases of EOC (5.7% [4/140]; data not shown).
Discussion
Similarities in the prevalence of PI3K alterations in West-
ern and Asian ovarian cancer [29-32], have raised an inter-
est to study these alterations in other ethnic groups. There
is a mixed report on the incidence of PIK3CA mutation in
ovarian cancer. Reported incidence of PIK3CA mutation
in epithelial ovarian cancer varies from 3.6% [30] to 12%
[31]. Our study showed a lower incidence of PIK3CA
mutations (3.9%), indicating that the PIK3CA gene muta-
tion is not a common mechanism in the activation of
PIK3CA in Middle Eastern ovarian tumors. Earlier studies
have reported PIK3CA gene amplification to be in the
range of 13 to 24.5% [10-13,33]. Only one study done on
a limited number of ovarian samples (n = 12) has
reported a higher incidence of PIK3CA amplification
(40%) [9]. On the other hand, our study demonstrated
PIK3CA amplification in ovarian tumors, with a relatively
high frequency (35.5%, Fig. 2), which suggests the major
role of PIK3CA amplification in the activation of these
ovarian cancers. Interestingly, there was an almost perfect
reciprocal association of the presence of gene amplifica-
tion and a somatic PIK3CA  mutations suggesting that
these mutations mainly occur in tumors without amplifi-
cation. In agreement with an earlier report by Woenck-
haus J et al., 2007 we also did not find any association
between PIK3CA amplification and p110 α protein
expression [13]. This lack of association could be
explained by transcriptional or post transcriptional mech-
anisms which finely tune the expression level of p110 α
expression. However, we found p110 α expression to be
correlated with p-AKT (P = 0.0260, Table 2) and a trend
was noted with the proliferation marker Ki-67 (P  =
0.0639).
Next, PTEN protein expression was investigated by immu-
nohistochemistry and 33 of 144 (22.9%, Fig. 3) EOCs
were showing PTEN inactivation, which was in concord-
ance with early report [34]. Correlation analysis between
PIK3CA  amplification and PTEN  protein loss by IHC
revealed that the majority of PIK3CA amplifications were
found in cases with high PTEN protein expression. This
data suggests that a single oncogenic alteration along this
pathway is sufficient to drive ovarian cell transformation.
As a read out of PI3K functional activation, we tested AKT
phosphorylation (activation) in EOC. Our findings show
that AKT is activated in a large proportion of EOCs
Table 3: Summary of individual cases of EOC with genetic alterations in PIK3CA, BRAF and KRAS genes
KRAS Mutation PIK3CA Mutation BRAF Mutation
Case
number
Exon/
codon
Nucleotide 
exchange
Amino 
acid
PIK3CA 
amplify
Exon/
codon
Nucleotide 
exchange
Amino 
acid
Exon/
codon
Nucleotide 
exchange
Amino 
acid
1 Normal 20/1047 CAT>CGTH i s > A r g
2 Normal 20/1056 GAT>AAT Asp>Asn
3 Normal 20/1115 TCT>TTTS e r > P h e
4 Normal 9/542 GAA>AAA Glu>Lys
5 Normal 9/545 GAG>AAG Glu>Lys
6 Normal 9/530 CAG>CGGG l n > A r g
7 1/12 GGT>GTTG L y > V a l N o r m a l
8 1/13 GGC>GACG L y > A s p N o r m a l
9 1/12 GGT>GATG L y > A s pN o r m a l
10 Normal 15/594 GGT>GATA s p > G l y
11 Normal 15/600 GTG>GGGV a l > G l y
12 Normal 15/600 GTG>GAGV a l > G l u
13 Amplified
14 Amplified
15 AmplifiedMolecular Cancer 2009, 8:51 http://www.molecular-cancer.com/content/8/1/51
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(52.1%), which reflect the activity of that pathway in our
EOC. However, no significant association was found
between AKT and PIK3CA mutation/amplification. Cur-
rently, multiple pathways have been implicated as having
role in AKT activation such as MAP kinase [35]. Further-
more, in agreement with an earlier report [36], we have
found significant correlation between fatty acid synthase
(FAS) protein expression and AKT activation in Middle
Eastern EOC (data not shown). Therefore, FAS overex-
pression might be one of the signaling pathways to acti-
vate AKT by a mechanism independent of the PI3K
pathway.
We were also interested in studying the relationship
between PI3K/AKT pathway and p53 (tumor suppressor
gene) since interactions between the p53 and PI3K/AKT
pathways play a significant role in the determination of
cell death/survival. Interrelation between these pathways
occurs through the transcriptional regulation of PTEN and
PIK3CA by p53, which is required for p53-mediated apop-
tosis [37-39]. P53 gene mutation is among the frequent
genetic alteration in ovarian carcinomas and its incidence
in Middle Eastern EOCs is 32%, which is relatively lower
to what has been reported in the west (50 to 80%) [40-
42]. Recently, Astanehe et al., 2008 have suggested that
p53 inactivation results in increases of PIK3CA transcripts
beyond those that result from amplification of PIK3CA
alone [37]. Thus, the combined effects of PIK3CA ampli-
fication and p53-mediated regulation of PIK3CA and
PTEN expression should contribute greatly to the
increased signaling through PI3K pathway in Middle East-
ern EOC.
We also analyzed MAPK signaling pathway by investigat-
ing the mutational status of key genes of that pathway,
BRAF and KRAS. Presence of KRAS and BRAF mutations
was significantly more common in serous borderline
ovarian tumors as compared to serous carcinomas (p =
0.0221; KRAS mutations) and (p < 0.0001; BRAF muta-
tions); data not shown). This is in concordance with ear-
lier reports [16,17]. The mutual exclusivity of BRAF and
KRAS mutations (Table 3) in our ovarian carcinoma is
consistent with previous findings in ovarian carcinoma,
melanoma, and colorectal carcinoma [43-45]. This also
supports the view that BRAF and KRAS mutations have
equivalent effects on tumorigenesis [44-46]. Although the
possibility that other downstream targets of BRAF are
mutated in conventional high-grade ovarian carcinomas
cannot be completely ruled out, it would appear that the
development of high grade serous carcinomas involves a
pathway distinct from the MAP kinase signaling pathway.
In examining the relationship between PI3K/AKT and
MAPK pathways, we found that PIK3CA amplification was
the single most common genetic alteration in our Middle
Eastern EOC cases and was mutually exclusive with gene
mutations in both pathways (PIK3CA, KRAS, and BRAF).
This represents strong genetic evidence that PIK3CA
amplification possesses similar oncogenic function as the
classical gene mutations in these pathways in ovarian can-
cer pathogenesis. The collective prevalence of genetic
alterations (PIK3CA amplification, mutation, PTEN pro-
tein loss) in the PI3K/Akt pathway was particularly high in
Middle Eastern EOC (60%), suggesting a significant role
of the PI3K/Akt pathway in the pathogenesis of EOC.
Conclusion
Our results showed that though mutation of PIK3CA is
not a common event in the EOCs, its amplification is very
common and may be a novel mechanism in activating the
PI3K/AKT pathway in some EOCs. High prevalence of
PI3K/AKT genetic alterations along with a low incidence
of KRAS and BRAF mutations in Middle Eastern ovarian
carcinomas, mutual exclusivity among genetic alterations
in PI3K/AKT and MAPK pathways, support the notion
that dysregulated PI3K/AKT pathways play an important
role in the pathogenesis of ovarian cancers regardless of
ethnic background. Understanding the alternative molec-
ular pathways that result in epithelial ovarian cancers will
allow specific biological targeting for therapy and preven-
tion of ovarian cancer.
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